What is new in MS spasticity research? Poster session highlights
作者： Ludwig Kappos , Franz Fazekas
DOI: 10.2217/NMT.15.59
关键词: Session (computer science) 、 Physical medicine and rehabilitation 、 Spasticity 、 Medicine 、 Physical therapy 、 Summit
摘要: Each year at the Experts Summit, recent relevant research in field of multiple sclerosis spasticity is featured poster sessions. Highlights 2015 session are presented.
futuremedicine.com 
sci-hub.se 参考文章(9)
Letizia Leocani, Arturo Nuara, Elise Houdayer, Irene Schiavetti, Ubaldo Del Carro, Stefano Amadio, Laura Straffi, Paolo Rossi, Vittorio Martinelli, Carlos Vila, Maria Pia Sormani, Giancarlo Comi, Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. Journal of Neurology. ,vol. 262, pp. 2520- 2527 ,(2015) , 10.1007/S00415-015-7878-1
A. Novotna, J. Mares, S. Ratcliffe, I. Novakova, M. Vachova, O. Zapletalova, C. Gasperini, C. Pozzilli, L. Cefaro, G. Comi, P. Rossi, Z. Ambler, Z. Stelmasiak, A. Erdmann, X. Montalban, A. Klimek, P. Davies, , A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis European Journal of Neurology. ,vol. 18, pp. 1122- 1131 ,(2011) , 10.1111/J.1468-1331.2010.03328.X
Francesco Patti, Carlos Vila, Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey. Neuroepidemiology. ,vol. 42, pp. 211- 218 ,(2014) , 10.1159/000360423
Peter Flachenecker, Thomas Henze, Uwe K. Zettl, Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity European Neurology. ,vol. 71, pp. 271- 279 ,(2014) , 10.1159/000357427
John Slof, Leonardo Ruiz, Carlos Vila, Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy Expert Review of Pharmacoeconomics & Outcomes Research. ,vol. 15, pp. 379- 391 ,(2015) , 10.1586/14737167.2015.1025759
John Slof, Adrien Gras, Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Review of Pharmacoeconomics & Outcomes Research. ,vol. 12, pp. 439- 441 ,(2012) , 10.1586/ERP.12.40
J. C. Hobart, A. Riazi, A. J. Thompson, I. M. Styles, W. Ingram, P. J. Vickery, M. Warner, P. J. Fox, J. P. Zajicek, Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain. ,vol. 129, pp. 224- 234 ,(2006) , 10.1093/BRAIN/AWH675
Kerri Alexandra Schoedel, Nancy Chen, Annie Hilliard, Linda White, Colin Stott, Ethan Russo, Stephen Wright, Geoffrey Guy, Myroslava K. Romach, Edward M. Sellers, A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Human Psychopharmacology-clinical and Experimental. ,vol. 26, pp. 224- 236 ,(2011) , 10.1002/HUP.1196
Thomas Henze, Sylvia von Mackensen, Gerald Lehrieder, Uwe K Zettl, Carmen Pfiffner, Peter Flachenecker, Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany Health and Quality of Life Outcomes. ,vol. 12, pp. 119- 119 ,(2014) , 10.1186/S12955-014-0119-Y